A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
NCT ID: NCT06667700
Last Updated: 2025-11-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
3082 participants
INTERVENTIONAL
2024-12-02
2031-01-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Molnupiravir (MK-4482) is a study medicine designed to stop the COVID-19 virus from copying itself in the body (multiplying). The goal of this study is to learn if molnupiravir prevents severe illness from COVID-19 more than placebo in people who are high risk.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Molnupiravir
Participants will receive 800 mg molnupiravir orally every 12 hours for 5 days (a total of 10 consecutive doses)
Molnupiravir
Molnupiravir administered orally as two 400 mg film-coated tablets every 12 hours for 5 days (a total of 10 consecutive doses)
Placebo
Participants will receive molnupiravir-matching placebo orally every 12 hours for 5 days (a total of 10 consecutive doses)
Placebo
Molnupiravir-matching placebo administered orally as two film-coated tablets every 12 hours for 5 days (a total of 10 consecutive doses)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Molnupiravir
Molnupiravir administered orally as two 400 mg film-coated tablets every 12 hours for 5 days (a total of 10 consecutive doses)
Placebo
Molnupiravir-matching placebo administered orally as two film-coated tablets every 12 hours for 5 days (a total of 10 consecutive doses)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has documentation of SARS-CoV-2 infection with sample collection ≤4 days prior to randomization
* Has initial onset of signs/symptoms attributable to COVID-19 for ≤4 days prior to the day of randomization and ≥2 of the following signs/symptoms attributable to COVID-19 on the day of randomization: cough, sore throat, nasal congestion, shortness of breath or difficulty breathing with exertion, muscle or body aches, fatigue, fever \>38.0°C or chills, nausea or vomiting or diarrhea, change in sense of smell or change in sense of taste, or headache
* Has ≥1 of the following characteristics or medical conditions associated with the highest risk of severe illness from COVID-19:
* Advanced age of ≥75 years of age
* Immunocompromised
* Neurocognitive or physical disability
* Has ≥3 characteristics or medical conditions which increase the risk of severe illness due to COVID-19 (e.g., chronic lung disease, obesity with body mass index (BMI) ≥35, diabetes)
* Is unable or unwilling to receive treatment with nirmatrelvir/ritonavir (NMV/r) due to 1 or more of the following:
* Is receiving drug(s) highly dependent on cytochrome P450 3A (CYP3A) for clearance and for which elevated concentrations are associated with serious and/or life-threatening consequences or drug(s) with a clinically significant drug-drug interaction for which co-administration is not possible
* Is receiving potent CYP3A inducers where significantly reduced nirmatrelvir or ritonavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance
* Has severe hepatic impairment
* Has experienced prior adverse reactions or hepatotoxicity to NMV/r that would preclude future use
* Has known or suspected NMV/r resistance
* Has uncontrolled HIV infection
* NMV/r is not approved/authorized in the participant's country or it is not accessible to participant (e.g., drug shortage)
* Is unwilling to receive treatment with NMV/r
Inclusion note: Participants may receive remdesivir as standard of care in addition to molnupiravir or placebo. If remdesivir is available and clinically appropriate per local clinical practice, investigators will aim to ensure that those who are most vulnerable to severe COVID-19 receive timely access to remdesivir as standard of care on this study.
Exclusion Criteria
* Has received or plans to receive SARS-CoV-2 directed oral antivirals or monoclonal antibodies for current episode of COVID-19 (other than study intervention and, if applicable, remdesivir as standard of care)
* Has ≥1 of the following signs/symptoms that are attributable to severe or critical COVID-19:
* Shortness of breath at rest
* Respiratory rate ≥30 breaths per minute
* Heart rate ≥125 beats per minute
* Peripheral oxygen saturation (SpO2) ≤93% on room air or on supplemental oxygen for a reason other than COVID-19 which has not increased since onset of COVID-19 signs/symptoms
* New or increasing need for supplemental oxygen: receiving \>4 liters/minute supplemental oxygen due to COVID-19 OR on supplemental oxygen for a reason other than COVID-19 which has increased due to COVID-19
* Has received a COVID-19 vaccine within 30 days prior to randomization
* Has a history of confirmed influenza, respiratory syncytial virus (RSV), or SARS-CoV-2 infection (with or without symptoms; excluding current infection) within 30 days prior to randomization
* Has known or suspected hypersensitivity to active or inactive ingredients of molnupiravir
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cullman Clinical Trials ( Site 3813)
Cullman, Alabama, United States
Helios Clinical Research ( Site 3826)
Paradise Valley, Arizona, United States
Absolute Clinical Research ( Site 3709)
Phoenix, Arizona, United States
Clinica de Salud del Valle de Salinas ( Site 3825)
Castroville, California, United States
Ascada Health PC dba Ascada Research ( Site 3750)
Fullerton, California, United States
Pacific Clinical Studies ( Site 3827)
Los Alamitos, California, United States
Valley Clinical Trials, Inc. ( Site 3707)
Northridge, California, United States
FOMAT Medical Research ( Site 3720)
Oxnard, California, United States
Paradigm Clinical Research, LLC ( Site 3785)
San Diego, California, United States
Optimus Medical ( Site 3817)
San Francisco, California, United States
Millennium Clinical Trials ( Site 3758)
Westlake Village, California, United States
Paradigm Clinical Research Centers, Inc ( Site 3718)
Wheat Ridge, Colorado, United States
Encore Medical Research of Boynton Beach ( Site 3701)
Boynton Beach, Florida, United States
Prestige Clinical Research Center ( Site 3722)
Coral Gables, Florida, United States
Indago Research & Health Center, Inc ( Site 3714)
Hialeah, Florida, United States
Prestige Clinical Research ( Site 3830)
Homestead, Florida, United States
Accel Research Sites Network - St. Pete-Largo Clinical Research Unit ( Site 3779)
Largo, Florida, United States
Clinical Site Partners, LLC dba Flourish Research ( Site 3717)
Leesburg, Florida, United States
Advanced Pulmonary Research Institute ( Site 3781)
Loxahatchee Groves, Florida, United States
Southern Clinical Research ( Site 3773)
Miami, Florida, United States
Florida Pharmaceutical Research and Associates ( Site 3763)
Miami, Florida, United States
Bio-Medical Research LLC ( Site 3804)
Miami, Florida, United States
Bright Research Center ( Site 3746)
Miami, Florida, United States
Miami Clinical Research ( Site 3729)
Miami, Florida, United States
Reed Medical Research ( Site 3761)
Miami, Florida, United States
Palm Springs Community Health Center ( Site 3757)
Miami Lakes, Florida, United States
Panax Clinical Research ( Site 3803)
Miami Lakes, Florida, United States
Combined Research Orlando Phase I-IV ( Site 3797)
Orlando, Florida, United States
CDC Research Institute ( Site 3716)
Port Saint Lucie, Florida, United States
New Tampa Health ( Site 3764)
Tampa, Florida, United States
Clinical Research Trials of Florida ( Site 3703)
Tampa, Florida, United States
Precision Research Center ( Site 3704)
Tampa, Florida, United States
Encore Medical Research - Weston ( Site 3708)
Weston, Florida, United States
Balanced Life Health Care Solutions/SKYCRNG ( Site 3713)
Lawrenceville, Georgia, United States
Renew Health Clinical Research ( Site 3760)
Snellville, Georgia, United States
Rophe Adult and Pediatric Medicine/SKYCRNG ( Site 3816)
Union City, Georgia, United States
Paradigm Clinical Research - Boise ( Site 3841)
Boise, Idaho, United States
Rush University Medical Center ( Site 3748)
Chicago, Illinois, United States
Duly Health and Care ( Site 3799)
Lombard, Illinois, United States
University of Louisville School of Medicine ( Site 3706)
Louisville, Kentucky, United States
Barnum Medical Research ( Site 3828)
Natchitoches, Louisiana, United States
Annapolis Internal Medicine - CCT Research ( Site 3700)
Annapolis, Maryland, United States
Kur Research - Columbia Medical ( Site 3767)
Columbia, Maryland, United States
Revival Research Institute, LLC ( Site 3835)
Dearborn, Michigan, United States
Michigan Center of Medical Research (MICHMER) ( Site 3734)
Farmington Hills, Michigan, United States
Henry Ford St John TM Center for Infectious Disease Research ( Site 3766)
Grosse Pointe Woods, Michigan, United States
Mankato Clinic ( Site 3842)
Mankato, Minnesota, United States
Prime Health and Wellness/SKYCRNG ( Site 3726)
Fayette, Mississippi, United States
SKY Integrative Medical Center/SKYCRNG ( Site 3740)
Ridgeland, Mississippi, United States
Nevada Health Centers ( Site 3840)
Carson City, Nevada, United States
WR-CRCN, LLC ( Site 3818)
Las Vegas, Nevada, United States
Saint Michael's Medical Center ( Site 3808)
Newark, New Jersey, United States
Holy Name Medical Center ( Site 3807)
Teaneck, New Jersey, United States
Weill Cornell Medical College ( Site 3814)
New York, New York, United States
Prime Global Research ( Site 3731)
The Bronx, New York, United States
OnSite Clinical Solutions ( Site 3784)
Charlotte, North Carolina, United States
Monroe Biomedical Research ( Site 3732)
Monroe, North Carolina, United States
IMA Clinical Research Mount Airy ( Site 3745)
Mount Airy, North Carolina, United States
Research Innovations, LLC ( Site 3712)
Beavercreek, Ohio, United States
Midlands Neurology & Pain Associates ( Site 3751)
Columbia, South Carolina, United States
Helios Clinical Research - JAC ( Site 3833)
Jackson, Tennessee, United States
Javara - Privia Medical Group Gulf Coast - The Woodlands HWH ( Site 3837)
Conroe, Texas, United States
South Texas Clinical Research ( Site 3815)
Corpus Christi, Texas, United States
Care United Research, LLC ( Site 3747)
Forney, Texas, United States
Houston Methodist Hospital ( Site 3800)
Houston, Texas, United States
Andres Garcia Zuniga, M.D., P.A. ( Site 3782)
Laredo, Texas, United States
LinQ Research ( Site 3824)
Pearland, Texas, United States
Crossroads Clinical Research-Family Practice ( Site 3739)
Victoria, Texas, United States
Velocity Clinical Research - Hampton ( Site 3744)
Hampton, Virginia, United States
Eastside Research Associates ( Site 3727)
Redmond, Washington, United States
CEMIC ( Site 0101)
Buenos Aires., Buenos Aires, Argentina
Hospital Italiano de Buenos Aires ( Site 0107)
Ciudad Autonoma de Buenos Aires., Buenos Aires, Argentina
Instituto de Investigaciones Clinicas Mar del Plata ( Site 0111)
Mar del Plata, Buenos Aires, Argentina
Nefra Medical Care - Moron ( Site 0109)
Morón, Buenos Aires, Argentina
Hospital Felicio Rocho (HFR) - Nucleo de Ciencias da Saude ( Site 0402)
Belo Horizonte, Minas Gerais, Brazil
Centro de Pesquisa Sao Lucas ( Site 0401)
Campinas, São Paulo, Brazil
Centro de Pesquisa Clinica II - ICHC - FMUSP ( Site 0403)
São Paulo, , Brazil
Medical Center Asclepius ( Site 0506)
Velingrad, Pazardzhik, Bulgaria
Medical Center Zdrave 1 ( Site 0509)
Kozloduy, Vratsa, Bulgaria
Medconsult Pleven - Lovech ( Site 0501)
Lovech, , Bulgaria
Medical Center Hera ( Site 0507)
Montana, , Bulgaria
MHAT "Dr. Stamen Iliev" Montana-Department of Pulmonology ( Site 0504)
Montana, , Bulgaria
Medconsult Pleven ( Site 0503)
Pleven, , Bulgaria
DKC V - Plovdiv ( Site 0508)
Plovdiv, , Bulgaria
SHATPPD Dr. Dimitar Gramatikov - Ruse EOOD ( Site 0502)
Rousse, , Bulgaria
Diagnostic Consultative Center 22 - Sofia ( Site 0500)
Sofia, , Bulgaria
Medical Center Hera EOOD ( Site 0505)
Sofia, , Bulgaria
IPS SURA San Diego ( Site 0806)
Medellín, Antioquia, Colombia
IPS Centro Científico Asistencial S.A.S ( Site 0800)
Barranquilla, Atlántico, Colombia
Clinica Colsanitas - Sede Reina Sofia ( Site 0807)
Bogotá, Bogota D.C., Colombia
Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia ( Site 0804)
Bogotá, Bogota D.C., Colombia
Sociedad De Oncología y Hematología Del Cesar SAS-Oncology ( Site 0801)
Valledupar, Cesar Department, Colombia
IMAT S.A.S ( Site 0805)
Montería, Departamento de Córdoba, Colombia
Fundación Valle del Lili ( Site 0803)
Cali, Valle del Cauca Department, Colombia
MeVac - Meilahti Vaccine Research Center ( Site 1200)
Helsinki, Uusimaa, Finland
Centre Hospitalier Universitaire Dijon Bourgogne - Hôpital F-Centre d'Investigation Clinique - Plur ( Site 1301)
Dijon, Bourgogne-Franche-Comté, France
CHU de Saint-Etienne ( Site 1302)
Saint Priest En Jarez, Pays de la Loire Region, France
centre hospitalier lyon sud ( Site 1303)
Pierre-Bénite, Rhone, France
Pitie Salpetriere University Hospital-Infectious Disease - Tropical Diseases ( Site 1300)
Paris, Île-de-France Region, France
Clinic Health - Batumi ( Site 1405)
Batumi, Adjara, Georgia
Family Medical Regional Center ( Site 1404)
Batumi, Adjara, Georgia
LTD High Technology Hospital Medcenter ( Site 1408)
Batumi, Adjara, Georgia
University Clinic of Innovative Medicine ( Site 1400)
Batumi, Adjara, Georgia
Caucasus Medical Centre ( Site 1406)
Tbilisi, Adjara, Georgia
New Hospitals ( Site 1409)
Tbilisi, , Georgia
Curatio Clinic - Main Location ( Site 1401)
Tbilisi, , Georgia
TUM Klinikum ( Site 1502)
Munich, Bavaria, Germany
Universitätsklinikum Frankfurt Goethe-Universität ( Site 1503)
Frankfurt am Main, Hesse, Germany
Universitaetsklinikum Koeln ( Site 1505)
Cologne, North Rhine-Westphalia, Germany
Campus Charite Mitte Nephrologie und Internistische Intensivmedizin ( Site 1501)
Berlin, State of Berlin, Germany
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola ( Site 1904)
Bologna, , Italy
Ospedale San Martino ( Site 1900)
Genova, , Italy
ASST Fatebenefratelli Sacco ( Site 1901)
Milan, , Italy
AOU Pisana- Ospedale Cisanello ( Site 1905)
Pisa, , Italy
National Hospital Organization Shimoshizu National Hospital ( Site 2007)
Yotsukaidō, Chiba, Japan
Tsuchiura Beryl Clinic ( Site 2009)
Tsuchiura, Ibaraki, Japan
National Hospital Organization Tokyo National Hospital ( Site 2003)
Kiyose, Tokyo, Japan
Sekino Hospital ( Site 2016)
Toshimaku, Tokyo, Japan
National Hospital Organization Kyushu Medical Center ( Site 2006)
Fukuoka, , Japan
Kumamoto Chuo Hospital ( Site 2002)
Kumamoto, , Japan
Morales Vargas Centro de Investigacion ( Site 2206)
León, Guanajuato, Mexico
CIO - Centro de Inmuno-Oncología de Occidente ( Site 2207)
Guadalajara, Jalisco, Mexico
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran-Departamento de Infectología ( Site 2203)
Mexico City, Mexico City, Mexico
Instituto Nacional de Salud Publica ( Site 2205)
Cuernavaca, Morelos, Mexico
Hospital Universitario "Dr. Jose Eleuterio Gonzalez"-Infectologia ( Site 2204)
Monterrey, Nuevo León, Mexico
Centro Multidisciplinario para el Desarrollo Especializado de la Investigacion Clinica en Yucatan ( Site 2202)
Mérida, Yucatán, Mexico
ICARO Investigaciones en Medicina ( Site 2200)
Chihuahua City, , Mexico
Arké SMO S.A de C.V-ARKE SMO S.A. de C.V. ( Site 2210)
Veracruz, , Mexico
CGM Research Trust ( Site 2307)
Christchurch, Canterbury, New Zealand
Pacific Clinical Research Network - Tasman ( Site 2304)
Nelson, Tasman District, New Zealand
Lakeland Clinical Trials Waikato ( Site 2302)
Nawton, Waikato Region, New Zealand
Lakeland Clinical Trials Wellington ( Site 2303)
Upper Hutt, Wellington Region, New Zealand
Pacific Clinical Research Network West Auckland ( Site 2301)
Auckland, , New Zealand
Optimal Clinical Trials North ( Site 2308)
Auckland, , New Zealand
Silverdale Medical Limited ( Site 2305)
Auckland, , New Zealand
Optimal Clinical Trials ( Site 2306)
Auckland, , New Zealand
Asociación Civil Selva Amazónica ( Site 2405)
Iquitos, Loreto, Peru
Clinica Ricardo Palma-Centro de Investigacion de Enfermedades Respiratorias Thorax ( Site 2404)
Lima, , Peru
PL Certus ( Site 2613)
Poznan, Greater Poland Voivodeship, Poland
In-Vivo Bydgoszcz ( Site 2601)
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
NZOZ GynCentrum - Oddział Kraków ( Site 2609)
Krakow, Lesser Poland Voivodeship, Poland
Penta Hospitals Przychodnie Wrocław Wejherowska ( Site 2611)
Wroclaw, Lower Silesian Voivodeship, Poland
NZOZ GynCentrum - Oddział Bielsko-Biała ( Site 2602)
Bielsko-Biala, Silesian Voivodeship, Poland
Clinical Medical Research ( Site 2604)
Katowice, Silesian Voivodeship, Poland
Holsamed ( Site 2603)
Katowice, Silesian Voivodeship, Poland
Investigadores del Este LLC ( Site 4001)
Humacao, , Puerto Rico
Miralles Clinical Research LLC ( Site 4004)
San Juan, , Puerto Rico
MV HEALTH SERVICES LLC ( Site 4003)
San Juan, , Puerto Rico
Spitalul Clinic de Boli Infecțioase și Tropicale Victor Babeș ( Site 2701)
Bucharest, București, Romania
Spitalul Clinic De Urgenta Prof Dr Agrippa Ionescu ( Site 2705)
Baloteşti, Ilfov, Romania
Centrul Medical SANA ( Site 2704)
Bucharest, , Romania
National Institute for Infectious Diseases Prof. Dr. Matei Bals ( Site 2706)
Bucharest, , Romania
Spitalul Clinic de Boli Infecțioase ( Site 2703)
Cluj-Napoca, , Romania
Spitalul Clinic de Boli Infecțioase ( Site 2702)
Constanța, , Romania
Wonju Severance Christian Hospital-Internal Medicine ( Site 3009)
Wŏnju, Kang-won-do, South Korea
Chonnam National University Hospital-Infectious Diseases ( Site 3008)
Gwangju, Kwangju-Kwangyokshi, South Korea
Korea University Ansan Hospital ( Site 3007)
Ansan-si, Kyonggi-do, South Korea
Gyeongsang National University Hospital ( Site 3005)
Jinju, Kyongsangnam-do, South Korea
Pusan National University Hospital-Internal Medicine ( Site 3010)
Pusan, Pusan-Kwangyokshi, South Korea
Kyungpook National University Chilgok Hospital-Division of Infectious Diseases ( Site 3002)
Deagu, Taegu-Kwangyokshi, South Korea
Korea University Anam Hospital ( Site 3001)
Seoul, , South Korea
Hallym University Kangnam Sacred Heart Hospital-Internal Medicine ( Site 3003)
Seoul, , South Korea
Korea University Guro Hospital ( Site 3006)
Seoul, , South Korea
Hospital General Universitario de Elche-Infectius Disease ( Site 3105)
Elche, Alicante, Spain
Hospital Germans Trias i Pujol ( Site 3101)
Badalona, Barcelona, Spain
EAP Osona Sud - Alt Congost S.L.P ( Site 3107)
Centelles, Barcelona, Spain
Hospital Universitari Vall d'Hebron ( Site 3102)
Barcelona, Catalonia, Spain
Hospital Santa Lucia-Medicina Infecciosas ( Site 3106)
Cartagena, Murcia, Spain
EAP Sardenya ( Site 3109)
Barcelona, , Spain
Hospital Universitario Infanta Leonor ( Site 3110)
Madrid, , Spain
HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO ( Site 3100)
Seville, , Spain
Kaohsiung Medical University Chung-Ho Memorial Hospital ( Site 3306)
Kaoshiung, Kaohsiung, Taiwan
Taoyuan General Hospital ( Site 3300)
Taoyuan, Taoyuan, Taiwan
Kaohsiung Veterans General Hospital ( Site 3307)
Kaohsiung City, , Taiwan
Taichung Veterans General Hospital ( Site 3305)
Taichung, , Taiwan
National Taiwan University Hospital ( Site 3301)
Taipei, , Taiwan
Tri-Service General Hospital ( Site 3304)
Taipei, , Taiwan
Chang Gung Memorial Hospital - Linkou Branch ( Site 3303)
Taoyuan District, , Taiwan
Faculty of Medicine Siriraj Hospital-Department of Medicine ( Site 3401)
Bangkok, Bangkok, Thailand
HIV Netherlands Australia Thailand Research Collaboration ( Site 3402)
Pathumwan, Bangkok, Thailand
EUROMEDCLINIC ( Site 3517)
Cherkasy, Cherkasy Oblast, Ukraine
MUNICIPAL NON-PROFIT ENTERPRISE CENTRAL CITY CLINICAL HOSPITAL OF CHERNIVTSI CITY COUNCIL ( Site 3513)
Chernivtsi, Chernihiv Oblast, Ukraine
Clinical medical and diagnostic center Limited Liability Company "Simedgroup" ( Site 3524)
Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ukraine
Regional Phthisiology and Pulmonology Center ( Site 3523)
Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ukraine
Private Enterprise Private Manufacturing Company Acinus-Medical and Diagnostic Centre ( Site 3537)
Kropyvnytskyi, Kirovohrad Oblast, Ukraine
Limited Liability Company Ukrainian Center of Tomotherapy-Clinical Trials Department ( Site 3512)
Kropyvnytskyi, Kirovohrad Oblast, Ukraine
Medical Center "Harmoniya Krasy" ( Site 3545)
Kyiv, Kyivska Oblast, Ukraine
Edelweiss Medics ( Site 3503)
Kyiv, Kyivska Oblast, Ukraine
Communal Non-Profit Enterprise "Kyiv City Clinical Hospital #1"-Department of Clinical Research ( Site 3514)
Kyiv, Kyivska Oblast, Ukraine
Medbud Clinic-Treatment prevention unit ( Site 3506)
Kyiv, Kyivska Oblast, Ukraine
Medical Center of Limited ( Site 3546)
Kyiv, Kyivska Oblast, Ukraine
Center of Family Medicine Plus ( Site 3502)
Kyiv, Kyivska Oblast, Ukraine
Polyclinic of Communal 4th city clinical hospital ( Site 3501)
Lviv, Lviv Oblast, Ukraine
Municipal non-profit enterprise "Lviv Territorial Medical Union "Multidisciplinary Clinical Hospital ( Site 3525)
Lviv, Lviv Oblast, Ukraine
University clinic of the National Pirogov Memorial Medical University ( Site 3547)
Vinnytsia, Vinnytsia Oblast, Ukraine
Scientific and research institute of invalid rehabilitation (education scientific and treatment base ( Site 3528)
Vinnytsia, Vinnytsia Oblast, Ukraine
Municipal Enterprise "Volyn Regional Clinical Hospital" of Volyn Regional Council ( Site 3530)
Lutsk, Volyn Oblast, Ukraine
Uzhhorod Municipal Multidisciplinary Clinical Hospital of Uzhhorod City Council ( Site 3538)
Uzhhorod, Zakarpattia Oblast, Ukraine
Medlight Clinic ( Site 3548)
Kyiv, , Ukraine
Kyiv Railway Clinical Hospital No.2 of Branch Health Center -Center of Clinical Trials ( Site 3549)
Kyiv, , Ukraine
Whiteladies Medical Group ( Site 3611)
Bristol, Bristol, City of, United Kingdom
Royal Devon & Exeter Hospital ( Site 3604)
Exeter, England, United Kingdom
Royal Victoria Infirmary ( Site 3608)
Newcastle, Newcastle Upon Tyne, United Kingdom
Oak Street Medical Practice ( Site 3612)
Norwich, Norfolk, United Kingdom
Lakeside Surgery ( Site 3600)
Northamptonshire, Northamptonshire, United Kingdom
Bicester Health Centre ( Site 3609)
Bicester, Oxfordshire, United Kingdom
Banbury Cross Health Centre ( Site 3610)
Oxford, Oxfordshire, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
Merck Clinical Trials Information
Protocol Plain Language Summary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-507227-36-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
U1111-1295-4678
Identifier Type: REGISTRY
Identifier Source: secondary_id
MK-4482-023
Identifier Type: OTHER
Identifier Source: secondary_id
jRCT2031250022
Identifier Type: REGISTRY
Identifier Source: secondary_id
4482-023
Identifier Type: -
Identifier Source: org_study_id